HALOZYME THERAPEUTICS, INC. 8-K

What Happened

• On January 28, 2026, Halozyme Therapeutics, Inc. filed an 8-K and issued a press release (and held a conference call) providing preliminary, unaudited estimates of its financial results for the year ended December 31, 2025 and updated 2026 guidance. Management emphasized these figures are preliminary, subject to completion of accounting close procedures, and may change before the audited Form 10-K is filed.
• The company estimated full-year 2025 revenue in the range of $1,385 million to $1,400 million, with royalty revenue, product sales, and collaboration revenue estimated separately (see details below).

Key Details

• 2025 Revenue (preliminary, unaudited): $1,385M – $1,400M.
• 2025 Royalties: $865M – $870M.
• 2025 Product Sales: $372M – $377M.
• 2025 Collaboration Revenue: $148M – $153M.
• Filing date and disclosures: 8-K furnished January 28, 2026; press release attached as Exhibit 99.1. The Form 8-K was signed by Nicole LaBrosse, SVP & Chief Financial Officer.

Why It Matters

• These preliminary numbers give investors an early view of Halozyme’s full-year 2025 performance—particularly that royalties represent the largest single component of the estimated revenue mix—which can influence near-term analyst models and expectations for earnings and cash flow.
• Because the estimates are unaudited and subject to change during the financial close and audit, investors should treat them as provisional and await the company’s audited Form 10-K for final results.